1-(2-甲基-1H-苯并咪唑-5-基)乙酮 | 13535-47-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 1-(2-甲基-1H-苯并咪唑-5-基)乙酮
• 英文名称: 1-(2-methyl-1H-benzo[d]imidazol-6-yl)ethanone
• 英文别名: 2-Methyl-6-acetylbenzimidazol；1-(2-methyl-1(3)H-benzoimidazol-5-yl)-ethanone；1-(2-methyl-3H-benzoimidazol-5-yl)-ethanone；1-(2-methyl-1H-benzo[d]imidazol-5-yl)ethanone；1-(2-methyl-3H-benzimidazol-5-yl)ethanone
• CAS: 13535-47-2
• 化学式: C₁₀H₁₀N₂O
• 分子量: 174.202
• InChiKey: KHMGLMZOBMOVRS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  45.8
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险性防范说明：
  P264,P280,P302+P352,P337+P313,P305+P351+P338,P362+P364,P332+P313
• 危险性描述：
  H315,H319

反应信息

• 作为反应物：
  描述：

  1-(2-甲基-1H-苯并咪唑-5-基)乙酮 在 氢溴酸 、 溴 、 溶剂黄146 作用下， 反应 0.5h， 以88%的产率得到2-bromo-1-(2-methyl-1H-benzo[d]imidazol-6-yl)ethanone hydrobromide
  参考文献：
  名称：

  [EN] KINASE INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE
  [FR] COMPOSÉS INHIBITEURS DE KINASE, COMPOSITIONS ET PROCÉDÉS D'UTILISATION

  摘要：

  本发明涉及具有以下结构的激酶抑制剂化合物：或其立体异构体、药用盐、氧化物或溶剂合物，其中R1、R2、X、n、R3、Y、Z、R4、R5、R6和=如本文所定义。本发明还涉及含有激酶抑制剂化合物的组合物，抑制细胞中激酶活性的方法，增加胰岛β细胞群体中细胞增殖的方法，治疗由于胰岛素分泌不足引起的病症的方法，以及治疗神经疾病的方法。

  公开号：

  WO2019100062A1
• 作为产物：
  描述：

  1-(3,4-二氨基苯基)乙酮 在 溶剂黄146 作用下， 生成 1-(2-甲基-1H-苯并咪唑-5-基)乙酮
  参考文献：
  名称：

  Borsche; Barthenheier, Justus Liebigs Annalen der Chemie, 1942, vol. 553, p. 250,257

  摘要：

  DOI：

文献信息

• HEPATITIS C VIRUS INHIBITORS
  申请人：Qiu Yao-Ling

  公开号：US20110064695A1

  公开（公告）日：2011-03-17

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The present invention relates to novel antiviral compounds represented herein above, pharmaceutical compositions comprising such compounds, and methods for the treatment or prophylaxis of viral (particularly HCV) infection in a subject in need of such therapy with said compounds.

  本发明公开了化合物的结构式（I），或其药学上可接受的盐、酯或前药： 这些化合物抑制RNA含病毒，特别是丙型肝炎病毒（HCV）。因此，本发明的化合物干扰丙型肝炎病毒的生命周期，并且也可用作抗病毒剂。本发明还涉及包含上述化合物的药物组合物，用于治疗患有HCV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HCV感染的方法。本发明涉及上述新型抗病毒化合物，包括含有这些化合物的药物组合物，以及用于治疗或预防受试者需要此类治疗的病毒（特别是HCV）感染的方法。
• [EN] SUBSTITUTED BICYCLIC AMINES FOR THE TREATMENT OF DIABETES<br/>[FR] AMINES BICYCLIQUES SUBSTITUÉES POUR LE TRAITEMENT DU DIABÈTE
  申请人：MERCK SHARP & DOHME

  公开号：WO2010056717A1

  公开（公告）日：2010-05-20

  Described herein are substituted bicyclic amines. In particular, described herein are substituted bicyclic amines that are effective as antagonists of SSTR5 and useful for the treatment, control or prevention of disorders responsive to antagonism of SSTR5, such as type 2 diabetes, insulin resistance, lipid disorders, obesity, atherosclerosis, metabolic syndrome, depression, and anxiety.

  本文描述了替代的双环胺。具体来说，本文描述了作为SSTR5拮抗剂有效的替代双环胺，用于治疗、控制或预防对SSTR5拮抗有响应的疾病，如2型糖尿病、胰岛素抵抗、脂质紊乱、肥胖、动脉粥样硬化、代谢综合征、抑郁症和焦虑症。
• Nitrogen-containing heterocyclic compound and use thereof
  申请人：Ikeura Yoshinori

  公开号：US20090156572A1

  公开（公告）日：2009-06-18

  The present invention relates to a compound represented by the formula wherein ring A is a nitrogen-containing heterocycle optionally further having substituent(s), ring B is an aromatic ring optionally having substituent(s), ring C is a cyclic group optionally having substituent(s), R 1 is a hydrogen atom, a hydrocarbon group optionally having substituent(s), an acyl group, a heterocyclic group optionally having substituent(s) or an amino group optionally having substituent(s), R 2 is an optionally halogenated C 1-6 alkyl group, m and n are each an integer of 0 to 5, m+n is an integer of 2 to 5, and is a single bond or a double bond, or a salt thereof and the like. Since the compound has a superior tachykinin receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of various diseases such as lower urinary tract diseases, gastrointestinal diseases, central nervous system diseases and the like.

  本发明涉及一种由下式表示的化合物：其中环A是含氮杂环，可选择地进一步具有取代基，环B是芳香环，可选择地具有取代基，环C是环状基团，可选择地具有取代基，R1是氢原子，一个碳氢基团，可选择地具有取代基，酰基，一个杂环基团，可选择地具有取代基或一个氨基团，可选择地具有取代基，R2是可选择卤代的C1-6烷基基团，m和n分别是0到5的整数，m+n是2到5的整数，是单键或双键，或其盐等。由于该化合物具有优越的催吐肽受体拮抗作用，可用作预防或治疗多种疾病的药物，如下尿道疾病、胃肠道疾病、中枢神经系统疾病等。
• FUSED HETEROARYL INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION
  申请人：Leonard Kristi Anne

  公开号：US20120129872A1

  公开（公告）日：2012-05-24

  This invention relates to thiazole I and its therapeutic and prophylactic uses, wherein the variables A, Q, J, R 1 , R 3 , and R 5 are defined in the specification. Disorders treated and/or prevented include rheumatoid arthritis.

  该发明涉及噻唑I及其治疗和预防用途，其中变量A、Q、J、R1、R3和R5在规范中有定义。治疗和/或预防的疾病包括类风湿性关节炎。
• Sesterterpene Compounds and Use Thereof
  申请人：Kang Heon Joong

  公开号：US20130274212A1

  公开（公告）日：2013-10-17

  The present invention relates to sesterterpene compounds, to the precursors thereof that are hydrolysable in a living body, or to the pharmaceutically acceptable salts thereof, and also relates to the prevention and treatment efficacy of the sesterterpene compounds with respect to non-insulin dependent diabetes mellitus, diabetic complications (renal failure and foot ulcers caused by diabetes), alcoholic, non-alcoholic, and viral fatty liver diseases, obesity, hyperlipidemia, atherosclerosis, cardiovascular diseases such as atherosclerotic stroke, and cerebropathies (Parkinsonism, schizophrenia and Alzheimer's disease). In addition, the present invention relates to compositions for functional foods, functional beverages, functional cosmetics, and functional feed.

  本发明涉及七萜化合物及其在生物体内可水解的前体物或其药学上可接受的盐，以及该七萜化合物在非胰岛素依赖性糖尿病、糖尿病并发症（由糖尿病引起的肾衰竭和足溃疡）、酒精性、非酒精性和病毒性脂肪肝疾病、肥胖症、高脂血症、动脉粥样硬化、动脉粥样硬化性中风、以及脑病（帕金森病、精神分裂症和阿尔茨海默病）的预防和治疗功效方面的应用。此外，本发明还涉及功能性食品、功能性饮料、功能性化妆品和功能性饲料的组合物。